^
    Back
    Association details:
    Biomarker:EGFR L858R + RBM10 Q595*
    Cancer:Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    bioRxiv
    Title:

    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

    Published date:
    10/27/2020
    Excerpt:
    we next followed a patient (Case #3) treated with neoadjuvant osimertinib on a clinical trial (NCT03433469) whose tumor harbored the EGFR L858R and RBM10 Q595* co-occurring mutations. Following two months of neo-adjuvant osimertinib treatment, we confirmed ...80% tumor cell viability in the osimertinib-treated
    DOI:
    10.1101/2020.10.26.356352